REG 2023

Regulatory Affairs Overview.

Knowing how, when, and where.
A smarter approach to Pharmaceutical Regulatory Affairs.

Download our Regulatory Affairs brochure…

The decisions you make about your regulatory strategy can fuel your growth, or create unnecessary obstacles. 

Successfully navigating regulatory requirements is more than simply following the rules, it is about understanding the complexities and implications of different procedures and requirements across world markets and linking regulatory intelligence and experience with your needs.

And we have the in-house expertise to develop and execute the right strategy worldwide across the EU, North America, LATAM, MENA, CIS, APAC regions and South Africa.

 

We can also support your internal regulatory and market access teams by supplementing any missing capacity or capability with a fast, agile, and tailored service.

Whether you’re a US-based biotech looking to reach specific or all markets, or you’re a more established European company needing guidance, our consultants can advise, plan, and deliver a better strategy to ensure your products are available to patients around the world.

Ready to contact us?

Focused solutions.
Designed to support a pan-EU/US development strategy.

Download our Regulatory Services brochure…

Services from early preclinical development to marketing authorization and product lifecycle management.

  • QA/QMS development.
  • Global PV strategies.
  • Regulatory roadmaps & strategies.
  • RA/PV/QA due-diligence.
  • Target Product Profiles.
  • SME designation.
  • Early FDA/EMA/UK engagements.
  • Orphan & pediatric strategies.

Arriello experts in Europe and the US work within a project team to provide coherent regulatory strategies and operational support.

We offer tailored and optimized services, leveraging the right solution, either in the US, Europe or combined.

Regulatory life cycle timeline. Services by stage and for all stages.

What our clients say about us.

Latest Regulatory Affairs Case Studies:

Regulatory Submissions, Orphan Drug Designation, Accelerated Approvals
Management of a Rare Disease Clinical Development Program.